Table 4.

Summary of AEs

Patients (N = 157)
Any patient with an AE, n (%)* 147 (94) 
Severity by event, number of events (%)*  
 Mild 1592 (74) 
 Moderate 502 (23) 
 Severe 62 (3) 
Patients reporting at least 1 related AE, n (%) 84 (54) 
Patients reporting at least 1 serious AE, n (%) 27 (17) 
Patients with an AE leading to withdrawal, n (%) 12 (8) 
Deaths 
Related AEs by patient in ≥5% of patients, n (%) 81 (53) 
 Abdominal pain upper 11 (7) 
 Arthralgia 9 (6) 
 Dyspepsia 9 (6) 
 Fatigue 8 (5) 
 Gastritis 8 (5) 
 Diarrhea 8 (5) 
 Nerve conduction studies abnormal 8 (5) 
Patients (N = 157)
Any patient with an AE, n (%)* 147 (94) 
Severity by event, number of events (%)*  
 Mild 1592 (74) 
 Moderate 502 (23) 
 Severe 62 (3) 
Patients reporting at least 1 related AE, n (%) 84 (54) 
Patients reporting at least 1 serious AE, n (%) 27 (17) 
Patients with an AE leading to withdrawal, n (%) 12 (8) 
Deaths 
Related AEs by patient in ≥5% of patients, n (%) 81 (53) 
 Abdominal pain upper 11 (7) 
 Arthralgia 9 (6) 
 Dyspepsia 9 (6) 
 Fatigue 8 (5) 
 Gastritis 8 (5) 
 Diarrhea 8 (5) 
 Nerve conduction studies abnormal 8 (5) 
*

Regardless of relationship to eliglustat.

Considered by investigator to be possibly, probably, or definitely related to eliglustat. Two related AEs in 2 patients were considered serious and possibly related to eliglustat (neither led to trial withdrawal): 1 peripheral neuropathy (moderate), 1 bowel obstruction from Meckel diverticulum (severe).

or Create an Account

Close Modal
Close Modal